用康格罗尔治疗心脏性休克患者的抗血小板治疗:系统性审查和单臂元分析
Jacopo D'Andria Ursoleo1, Luca Baldetti2, Marina Pieri1,3
1Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
康格洛尔是一种亲肠道P2Y12抑制剂,在急性心肌梗塞心脏冲击患者中显示出可行性和安全性,血栓栓塞事件较低,但出血率较高. 最佳剂量仍然不确定.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 穿皮冠状动脉干预 (PCI) 对急性心肌梗塞 (AMI) 心脏病性休克 (CS) 至关重要.
- 标准的双重抗血小板治疗在CS患者中存在风险,原因是血液动力学不稳定性和出血问题.
- 亲肠道,短效P2Y12抑制剂在急性心脏护理中提供了药理动力学优势.
研究的目的:
- 在AMI-CS患者中系统地审查和元分析静脉注射康格罗尔的安全性和疗效.
- 为了评估主要出血率,支架/任何血栓形成,以及与 cangrelor 使用相关的医院存活率.
主要方法:
- 按照PRISMA指南进行系统审查和单臂元分析.
- 包括2017-2023年间发表的10项研究 (678名患者),报告了AMI-CS.中的静脉注射.
- 对结果的分析,包括主要出血,血栓形成 (支架/任何支架) 和医院生存率.
主要成果:
- 综合的主要出血率为17% (11-23% CI).
- 支架血栓瘤和任何血栓瘤的汇总率分别为1% (0.3-2.3% CI) 和3% (0.4-7% CI).
- 综合医院生存率为66% (59-73% CI);26%的患者接受了机械循环支持.
结论:
- 在AMI-CS患者中,静脉注射康格罗尔是可行的和安全的,显示出血栓栓塞并发症的发病率较低.
- 出血并发症发生的频率高于血栓事件.
- 对于AMI-CS患者来说,康格洛尔的最佳剂量需要进一步的研究和标准化.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
